EXPERIENCE OF MANAGING ANEMIA IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

DOI Web Site 16 References

Bibliographic Information

Other Title
  • 血管免疫芽球性T細胞リンパ腫に伴う貧血管理の経験

Search this article

Abstract

<p>【Background】Anemia in angioimmunoblastic T-cell lymphoma (AITL) is caused by bone marrow involvement of tumor cells, pure red cell aplasia, or autoimmune hemolytic anemia. We present the results of transfusion therapy in two AITL cases. 【Case 1】An 86-year-old male was diagnosed with AITL by lymph node biopsy. Hemoglobin level was 8.9 mg/dl. Direct anti-globulin test (DAT) and indirect anti-globulin test (IAT) were positive, and a pan-agglutinin pattern was shown on a blood antibody detection test. Oral anti-tumor therapy and steroids were started, which were effective for 6 months. IAT titer reduced and transfusion was spared. 【Case 2】A 75-year-old male with eruption and fever was diagnosed with AITL. Tumor cells infiltrated the bone marrow. Hemoglobin level was 8.5 mg/dl. Both DAT and IAT were positive, and a pan-agglutinin pattern was shown on a blood antibody detection test. After three cycles of systemic chemotherapy, IAT titer was reduced. Transfusion of 34 units of red blood cells (RBCs) and 80 units of platelet concentrate (PC) were needed. 【Discussion】Blood transfusion was spared by therapeutic effects in case 1. Bone marrow suppression and hyper-destruction of blood cells resulted in case 2. Transfusion effectiveness may be reduced in activated AITL.</p>

Journal

References(16)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top